Acer Therapeutics Inc. (ACER): Price and Financial Metrics
GET POWR RATINGS... FREE!
ACER POWR Grades
- ACER scores best on the Growth dimension, with a Growth rank ahead of 91.43% of US stocks.
- The strongest trend for ACER is in Momentum, which has been heading down over the past 30 weeks.
- ACER's current lowest rank is in the Momentum metric (where it is better than 5.04% of US stocks).
ACER Stock Summary
- ACER has a higher market value than just 4.77% of US stocks; more precisely, its current market capitalization is $34,630,790.
- The ratio of debt to operating expenses for Acer Therapeutics Inc is higher than it is for about merely 0.4% of US stocks.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for ACER comes in at -44.35% -- higher than that of only 6.42% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Acer Therapeutics Inc are DAIO, LCTX, PDEX, CSLT, and EPZM.
- Visit ACER's SEC page to see the company's official filings. To visit the company's web site, go to www.acertx.com.
ACER Valuation Summary
- ACER's price/sales ratio is 9.4; this is 147.37% higher than that of the median Healthcare stock.
- Over the past 188 months, ACER's price/sales ratio has gone NA NA.
- Over the past 188 months, ACER's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for ACER.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ACER | 2021-08-31 | 9.4 | 4.8 | -2.2 | -0.9 |
| ACER | 2021-08-30 | 9.1 | 4.7 | -2.1 | -0.8 |
| ACER | 2021-08-27 | 9.1 | 4.7 | -2.1 | -0.8 |
| ACER | 2021-08-26 | 9.2 | 4.7 | -2.2 | -0.8 |
| ACER | 2021-08-25 | 9.2 | 4.7 | -2.2 | -0.8 |
| ACER | 2021-08-24 | 9.2 | 4.7 | -2.2 | -0.8 |
ACER Growth Metrics
- The 3 year revenue growth rate now stands at -100%.
- Its 4 year net income to common stockholders growth rate is now at -143.78%.
- Its 4 year price growth rate is now at -84.36%.
The table below shows ACER's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-06-30 | 3.998133 | 0.915877 | -16.90639 |
| 2021-03-31 | 3.998133 | -8.952031 | -19.44992 |
| 2020-12-31 | 0 | -17.02742 | -22.88545 |
| 2020-09-30 | 0 | -17.13891 | -21.80405 |
| 2020-06-30 | 0 | -20.0669 | -21.12727 |
| 2020-03-31 | 0 | -24.82641 | -26.39797 |
ACER Price Target
For more insight on analysts targets of ACER, see our ACER price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $10.00 | Average Broker Recommendation | 1.75 (Moderate Buy) |
ACER Stock Price Chart Interactive Chart >
ACER Price/Volume Stats
| Current price | $2.37 | 52-week high | $5.39 |
| Prev. close | $2.42 | 52-week low | $2.28 |
| Day low | $2.36 | Volume | 73,000 |
| Day high | $2.46 | Avg. volume | 612,453 |
| 50-day MA | $2.54 | Dividend yield | N/A |
| 200-day MA | $2.91 | Market Cap | 33.91M |
Acer Therapeutics Inc. (ACER) Company Bio
Acer Therapeutics Inc., formerly Opexa Therapeutics, develops therapies for the treatment of serious ultra-rare diseases with critical unmet medical needs. The company offers Celiprolol for vascular ehlers-danlos syndrome and ACER-001 for maple syrup urine disease. It also offers advancing ACER-001 for the treatment of urea cycle disorders. The company was founded in 2013 and is based in Cambridge, Massachusetts.
Latest ACER News From Around the Web
Below are the latest news stories about Acer Therapeutics Inc that investors may wish to consider to help them evaluate ACER as an investment opportunity.
Acer Therapeutics Inc. (NASDAQ:ACER): Are Analysts Optimistic?Acer Therapeutics Inc. ( NASDAQ:ACER ) is possibly approaching a major achievement in its business, so we would like to... |
FDA Approves NDA for Acer Therapeutics’ ACER-001; Shares RiseShares of Acer Therapeutics Inc. (ACER) closed 16.5% higher on Wednesday and then declined 5.51%, at the time of writing, in early trade on Thursday. The stock price moved after the pharmaceutical company and its collaboration partner, Relief Therapeutics Holding SA, received the U.S. Food and Drug Administration’s (FDA) green light to file the New Drug Application (NDA) for ACER-001. ACER-001 (sodium phenylbutyrate) is designed for the treatment of patients with various inborn errors of metabolism, including Urea Cycle Disorders (UCDs) and Maple Syrup Urine Disease (MSUD). The Prescription Drug User Fee Act (PDUFA) target action date of June 5, 2022, has been assigned by the FDA. |
FDA Approves NDA for Acer Therapeutics ACER-001; Shares RiseShares of Acer Therapeutics Inc. (ACER) closed 16. The post FDA Approves NDA for Acer Therapeutics ACER-001; Shares Rise appeared first on Smarter Analyst . |
Acer Therapeutics Receives Notice of Allowance of Key U.S. Patent Application Covering ACER-001 FormulationNotice of allowance of ACER-001 formulation composition of matter patent application strengthens proprietary position in U.S. until 2036 Notice of allowance of ACER-001 formulation composition of matter patent application strengthens proprietary position in U.S. until 2036 |
Acer's (ACER) NDA for ACER-001 in UCD Gets FDA AcceptanceThe FDA accepts Acer's (ACER) NDA for ACER-001 (sodium phenylbutyrate) for the treatment of patients with urea cycle disorders. A decision is due on Jun 5, 2022. Stock up. |
ACER Price Returns
| 1-mo | -7.42% |
| 3-mo | 2.60% |
| 6-mo | -18.28% |
| 1-year | -14.75% |
| 3-year | -89.61% |
| 5-year | -93.34% |
| YTD | -9.54% |
| 2020 | -34.66% |
| 2019 | -80.07% |
| 2018 | 45.27% |
| 2017 | 45.45% |
| 2016 | -66.79% |
Loading social stream, please wait...